

Q1 2023 *results*



“We have started 2023 with strong results, delivering double-digit sales growth across our Specialty Care, Vaccines and Consumer Healthcare businesses. With two best in class launches this year and the acceleration of our early-mid stage pipeline, we are well underway.”

Paul Hudson

Chief Executive Officer, Sanofi

Q1 2023 company sales

€10,222m (+5.5% at constant exchange rates, +5.7 on a reported basis)

Q1 2023 business earnings per share

€2.16 (+11.9% at constant exchange rates, +11.3 on a reported basis)

Sales by global business unit



Specialty Care

€4,288m



Vaccines

€1,167m



General Medicines

€3,272m



Consumer Healthcare

€1,495m

sanofi

Q1 2023 *results*

Sales by geography

US €4,069m	Europe €2,576m	Rest of the World €3,577m
---------------	-------------------	------------------------------

Social impact



Access to medicines

Sanofi launched *A Million Conversations*, a global initiative to rebuild trust in healthcare with underrepresented, marginalized communities.



Accelerating efforts to address climate change

Sanofi inaugurated its first self-consumption photovoltaic park on its Montpellier site in France.

For further information on Q1 2023 results and definitions of financial indicators, please refer to the press release issued on April 27, 2023 at: www.sanofi.com/en/investors

sanofi